Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. - Wikidata - wikimedia - TriplyDB

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.

http://www.wikidata.org/entity/Q34550827

about

Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer Recent progress in pancreatic cancer Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma Curcumin AntiCancer Studies in Pancreatic Cancer Chemoradiotherapy for locally advanced pancreatic cancer patients: is it still an open question?Prognostic value of lymph node metastases detected during surgical exploration for pancreatic or periampullary cancer: a systematic review and meta-analysis Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan Local Ablative Strategies for Ductal Pancreatic Cancer (Radiofrequency Ablation, Irreversible Electroporation): A Review Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians Perspectives in the treatment of pancreatic adenocarcinoma Albumin-bound paclitaxel in solid tumors: clinical development and future directions Management of borderline and locally advanced pancreatic cancer: where do we stand?Imaging and Therapy of Pancreatic Cancer with Phosphatidylserine-Targeted Nanovesicles Systemic treatment for inoperable pancreatic adenocarcinoma: review and update Interplay between smoking-induced genotoxicity and altered signaling in pancreatic carcinogenesis Systemic therapies for pancreatic cancer--the role of pharmacogenetics Pancreatic cancer treatment and research: an international expert panel discussion.Systematic Review of Resection Rates and Clinical Outcomes After FOLFIRINOX-Based Treatment in Patients with Locally Advanced Pancreatic Cancer The Triple-Code Model for Pancreatic Cancer: Cross Talk Among Genetics, Epigenetics, and Nuclear Structure Activator protein 1 promotes gemcitabine‑induced apoptosis in pancreatic cancer by upregulating its downstream target Bim Gemcitabine plus erlotinib for advanced pancreatic cancer: a systematic review with meta-analysis Predictive modeling of in vivo response to gemcitabine in pancreatic cancer Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer.Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison.A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer.Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer.Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study.Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses.Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer.Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study Phase I dose escalation study of gemcitabine plus irinotecan in advanced solid tumors.Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506.A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research.Prospective phase II trial of gemcitabine in combination with irinotecan as first-line chemotherapy in patients with advanced biliary tract cancer.A Phase II Trial of Gemcitabine plus Capecitabine for Patients with Advanced Pancreatic Cancer Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer?Neoadjuvant gemcitabine-based accelerated hyperfractionation chemoradiotherapy for patients with borderline resectable pancreatic adenocarcinoma.Intravenous ω-3 Fatty Acids Plus Gemcitabine.

P2860

Q24240739-22280147-F322-491A-8BCF-FDADD595CBD9 Q24245085-908F04E5-50AD-41F3-9A49-64AFBCB7ED79 Q24626346-F2100857-2555-4E43-9D54-C75EF979DEA8 Q24627664-66FA63F5-8446-49C9-BB24-29B1116A21E4 Q26738714-C2E5310A-8C9A-475C-8F51-651FC6E8C1C1 Q26746031-6B34DC51-E8FE-41DF-A684-B1937248CB24 Q26747108-49559DF2-BC0F-4BFA-A05C-D1D8DD2EB3A8 Q26751368-BF9D521F-3D83-4707-B13C-3B7250B12178 Q26765288-72D08D63-8B6D-4A0E-8CD6-CDA52DA6B185 Q26767041-5576F050-5945-4E03-9C38-20C108A08C8B Q26797248-85B9D49A-1704-4577-B07B-ED21EB0B7B78 Q26798674-2A28567B-1D5E-4FF7-8E27-C116F9F19D70 Q26825414-2D3149EC-F2C6-4B8F-A25F-AB498DA8B20F Q26828959-97C8146D-8F77-4DCF-85AA-177D16D011FB Q26830913-D9C0E364-B4BF-4484-9A25-6B516F09A93F Q26996794-068E99E7-6D35-4D31-BC97-8D3A778E83A8 Q27021716-638A9409-E283-4E28-B1C6-9F961867FDC5 Q27690868-3937897D-9D6E-4B20-939A-5AEDFCD94976 Q28072210-8A9B1A89-8BF1-4A4B-B6E4-CBCB0CBF7D0A Q28084785-F74B67D9-383E-463F-8B4A-757BE1A157F0 Q28468378-16E0D920-9E96-4427-A3D4-14A0825D3E90 Q28487656-75A69172-3858-4A5B-B64D-61F6963E5043 Q28533633-71EAEDE1-276A-4B76-B2B7-223964AE37FB Q29616728-407752E5-3567-4A9A-81C0-3598E250C285 Q33326148-1CB10596-513E-4E76-93F2-4C1BF8AAA98C Q33350085-6F6E7A57-B307-49B8-9E4E-10710762A498 Q33367733-DB79FD2C-95E5-4411-9C21-8B1CC13F0041 Q33370390-2DFE0C10-75D1-476D-A87F-2ADE451F4DE1 Q33371000-7EF2B112-A002-469A-82D0-88EE0B7B9D96 Q33380084-2829B189-4C04-482B-B5EA-492485A401D6 Q33382236-DF4C4617-BBEE-406E-A58B-1CA6F132C36A Q33384793-6A73DE1C-3F56-46C5-92FF-48C8B71188B0 Q33387673-ADB442F9-8227-4763-B93C-5B6B67289D08 Q33388392-8DF620FC-2F25-43E2-B1AB-8A61D32D07C6 Q33394505-3DFD76CB-ECCC-4BAC-8C49-BC605C2B7C4C Q33395417-216D030D-A67B-44C1-A630-D4798874E8CB Q33402374-D1EA4B99-5A4F-433F-A664-D3AFD0DB18FC Q33403498-ECD2604A-154B-4E4D-A345-A041AB92B6B3 Q33418870-B2362198-0FE3-4336-B0E1-9FA921CEBA98 Q33424793-C867C04D-093D-4D5B-8706-E342E83BAAFE

P2860

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.

http://www.wikidata.org/entity/Q34550827

description

2004 nî lūn-bûn

@nan

2004 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Irinotecan plus gemcitabine re ...... increased tumor response rate.

@ast

Irinotecan plus gemcitabine re ...... increased tumor response rate.

@en

Irinotecan plus gemcitabine re ...... increased tumor response rate.

@nl

type

label

Irinotecan plus gemcitabine re ...... increased tumor response rate.

@ast

Irinotecan plus gemcitabine re ...... increased tumor response rate.

@en

Irinotecan plus gemcitabine re ...... increased tumor response rate.

@nl

prefLabel

Irinotecan plus gemcitabine re ...... increased tumor response rate.

@ast

Irinotecan plus gemcitabine re ...... increased tumor response rate.

@en

Irinotecan plus gemcitabine re ...... increased tumor response rate.

@nl

P1433

Q34550827-7FF55228-64F0-44C1-B074-BA537AD45527

P1476

Q34550827-8602E5EB-CF0D-4529-988C-494274578300

P2093

Q34550827-11038852-23E5-43AC-A321-331E534EFEA5

Q34550827-1F0D66E5-BD43-4710-BA9E-2A44BD24944B

Q34550827-232A833E-7B51-4575-AE26-817297017DD4

Q34550827-41537F28-6A44-453D-9FA6-4659913647CE

Q34550827-42781467-5FB6-4CFB-8672-22FDBDBEF6B4

Q34550827-4EF15186-9BF1-42D5-B4AC-EC464918F2B2

Q34550827-7B819D9C-60D6-44D8-A053-C01E8BDEC448

Q34550827-8A218B92-2D1E-4A4D-9F20-486E996B496B

Q34550827-B9F8C6B7-43E5-47C4-8D03-9F46BD964A8C

Q34550827-C153991D-E9FC-4DE4-B49B-E37D31E1CBD2

P304

Q34550827-76FDF295-59CD-4F0A-81BF-5A797F8AA1F2

P31

Q34550827-62302C94-412E-4AC1-A1DF-445C5BEC3870

P356

Q34550827-DB680AFD-2433-4161-8897-78D662ED46CE

P407

Q34550827-AC6D6B65-5615-4F2F-9F1E-43C7769C980F

P433

Q34550827-20F86993-1992-409E-B197-FB45734F4EF6

P478

Q34550827-863C2AD3-A670-4521-AC62-2D634267C4B5

P577

Q34550827-E15A9AAE-F144-4CFC-A9BB-1D6B961F9305

P698

Q34550827-A4786F00-2D0C-436E-B697-40C24AC62994

P356

JCO.2004.12.082

P1433

Journal of Clinical Oncology

P1476

Irinotecan plus gemcitabine re ...... increased tumor response rate.

@en

P2093

Adele Morganti

http://www.w3.org/2001/XMLSchema#string

Caio M Rocha Lima

http://www.w3.org/2001/XMLSchema#string

G Mark Jeffrey

http://www.w3.org/2001/XMLSchema#string

Gabriela Gruia

http://www.w3.org/2001/XMLSchema#string

Langdon L Miller

http://www.w3.org/2001/XMLSchema#string

Laura A Cisar

http://www.w3.org/2001/XMLSchema#string

Mark R Green

http://www.w3.org/2001/XMLSchema#string

Nicoletta Orlando

http://www.w3.org/2001/XMLSchema#string

Robert Rotche

http://www.w3.org/2001/XMLSchema#string

Wilson H Miller

http://www.w3.org/2001/XMLSchema#string

P304

3776-3783

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2004.12.082

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P577

2004-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15365074

http://www.w3.org/2001/XMLSchema#string